JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic model for hepatocellular carcinoma based on necroptosis-related genes and analysis of drug treatment responses

  • 0Department of Economics, Jinan University, Guangzhou, 510632, China.
Heliyon +

|

September 12, 2024

|

September 12, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a new risk model using necroptosis-related genes to predict survival and immunotherapy response in liver cancer (HCC). The model identifies potential drug sensitivities for personalized treatment strategies.

Area Of Science

  • Oncology
  • Molecular Biology
  • Immunology

Background

  • Necroptosis plays a critical role in liver cancer development, metastasis, and immune evasion.
  • Liver cancer subtypes are influenced by hepatocyte apoptosis or necroptosis.
  • Analysis of necroptosis-related genes in hepatocellular carcinoma (HCC) is limited.

Purpose Of The Study

  • To develop a risk scoring model for HCC based on necroptosis-related genes.
  • To validate the model's predictive power for overall survival and immunotherapy efficacy in HCC.
  • To analyze drug treatment responses in different HCC subtypes.

Main Methods

  • Utilized TCGA data for liver cancer patients, including clinical information and RNA-seq.
  • Identified differentially expressed necroptosis-related genes and performed GO/KEGG enrichment.
  • Employed Cox regression and LASSO analysis to build and validate a prognostic model.
  • Conducted immune cell correlation analysis and ssGSEA.
  • Screened potential drugs for HCC based on subtype-specific sensitivity.

Main Results

  • Identified 19 differentially expressed necroptosis-related genes.
  • Constructed a 3-gene predictive model demonstrating strong performance in risk stratification and survival prediction.
  • ssGSEA analysis revealed significant immune cell differences.
  • Evaluated 55 immunotherapy drugs, identifying distinct sensitivities for drugs like Bleomycin and Obatoclax. Mesylate across HCC subtypes.

Conclusions

  • The developed necroptosis-based risk model effectively predicts prognosis and immunotherapy response in HCC.
  • Drug sensitivity analysis provides valuable insights for personalized treatment strategies in HCC.
  • This research offers a foundation for targeted therapies and improved clinical management of liver cancer.

Keywords: